Hyku Biosciences Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $8.61M

  • Investors
  • 7

Hyku Biosciences General Information

Description

Developer of small-molecule therapeutics with novel mechanisms of action intended to inhibit proteins that drive disease progression potently. The company identifies compounds that covalently bind to non-cysteine amino acids to facilitate the development of novel therapies that can address current challenges associated with many disease targets, including selectivity, druggability, and resistance, enabling patients to improve their lives by pushing the scientific boundaries of covalent medicines.

Contact Information

Website
www.hykubiosciences.com
Formerly Known As
Umbra Therapeutics, Endor Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5 Burlington Woods Drive
  • Suite 103 A
  • Burlington, MA 01803
  • United States
+1 (877)
Primary Industry
Drug Discovery
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 5 Burlington Woods Drive
  • Suite 103 A
  • Burlington, MA 01803
  • United States
+1 (877)

Hyku Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hyku Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 13-Aug-2026 $8.61M Completed Generating Revenue
1. Seed Round 12-Nov-2024 Completed Startup
To view Hyku Biosciences’s complete valuation and funding history, request access »

Hyku Biosciences Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed 2
Seed
To view Hyku Biosciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Hyku Biosciences Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

Hyku Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025053850-A1 Covalent kras-binding compounds for medical treatment Inactive 08-Sep-2023
CA-3210298-A1 Covalent binding compounds for the treatment of disease Pending 05-Mar-2021
US-20240165239-A1 Covalent binding compounds for the treatment of disease Inactive 05-Mar-2021
US-20230406853-A1 Covalent cdk2-binding compounds for therapeutic purposes Pending 05-Mar-2021
US-20230406854-A1 Covalent kras-binding compounds for therapeutic purposes Pending 05-Mar-2021 C07D471/04
To view Hyku Biosciences’s complete patent history, request access »

Hyku Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hyku Biosciences Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Chugai Venture Fund Corporate Venture Capital Minority
Droia Ventures Venture Capital Minority
Eisai Innovation Corporate Venture Capital Minority
KB Investment Venture Capital Minority
Novartis Venture Fund Corporate Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Hyku Biosciences FAQs

  • When was Hyku Biosciences founded?

    Hyku Biosciences was founded in 2021.

  • Where is Hyku Biosciences headquartered?

    Hyku Biosciences is headquartered in Burlington, MA.

  • What is the size of Hyku Biosciences?

    Hyku Biosciences has 16 total employees.

  • What industry is Hyku Biosciences in?

    Hyku Biosciences’s primary industry is Drug Discovery.

  • Is Hyku Biosciences a private or public company?

    Hyku Biosciences is a Private company.

  • What is the current valuation of Hyku Biosciences?

    The current valuation of Hyku Biosciences is .

  • What is Hyku Biosciences’s current revenue?

    The current revenue for Hyku Biosciences is .

  • How much funding has Hyku Biosciences raised over time?

    Hyku Biosciences has raised $72.6M.

  • Who are Hyku Biosciences’s investors?

    Chugai Venture Fund, Droia Ventures, Eisai Innovation, KB Investment, and Novartis Venture Fund are 5 of 7 investors who have invested in Hyku Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process